COMPARISON
Cetrorelix vs Leuprolide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Cetrorelix is authorised or registered in 10 and Leuprolide in 8 of the 10 registers read. Cetrorelix: No trial states a phase. Leuprolide: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). 6 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cetrorelix | Leuprolide | |
|---|---|---|
| Registered trials differs | 140 clinicaltrials.gov · 2026-10-03 | 520 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: cetrorelix acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vabrinty openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 1999-04-12 ema · 2026-10-03 | Not checked no record of "authorisedOn" for leuprolide |
| ATC code differs | H01CC02 ema · 2026-10-03 | Not checked no record of "atcCode" for leuprolide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cetrorelix | placebo | Leuprolide | placebo |
|---|---|---|---|---|
| Back pain | 6.2% | 6.4% | 17.0% | 15.3% |
| Hypertension | 4.7% | 5.5% | 16.4% | 15.1% |
| Arthralgia | 4.2% | 4.6% | 27.5% | 20.9% |
| Nasopharyngitis | 8.9% | 8.7% | - | - |
| Injection site pain | 8.5% | 3.7% | - | - |
| Headache | 7.3% | 7.3% | - | - |
| Upper respiratory infection | 6.9% | 6.0% | - | - |
| Diarrhea | 6.0% | 2.8% | - | - |
| Musculoskeletal pain | 6.0% | 2.8% | - | - |
| PSA increased | 5.6% | 2.3% | - | - |
| Hot flush | - | - | 68.8% | 57.3% |
| Fatigue | - | - | 42.8% | 32.8% |
| Fall | - | - | 20.4% | 14.1% |
| Diarrhoea | - | - | 13.9% | 8.5% |
| Asthenia | - | - | 11.0% | 5.9% |
| Pain in extremity | - | - | 11.0% | 10.2% |
| Dizziness | - | - | 11.0% | 10.5% |
Trial register Cetrorelix: 2 placebo-controlled trials; Leuprolide: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cetrorelix side effects · Leuprolide side effects
LEGAL STATUS
Approval in each country read
| Country | Cetrorelix | Leuprolide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
6 registered trials include both
| NCT04094467 | Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection UNKNOWN · updated 2020-03-25 |
|---|---|
| NCT01669291 | Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation COMPLETED · updated 2014-06-04 |
| NCT01948804 | The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization. UNKNOWN · updated 2014-01-15 |
| NCT00883766 | Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1 TERMINATED · updated 2012-07-20 |
| NCT01595334 | Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity UNKNOWN · updated 2012-05-25 |
| NCT00505817 | GnRH Agonist and Antagonists in an Oocyte Donation Program COMPLETED · updated 2009-01-12 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.